小细胞肺癌内科治疗新进展

Advances in the internal medicine treatment of small cell lung cancer

小细胞肺癌(small cell lung cancer,SCLC)具有极高的增殖率、较强的早期转移倾向和较差的预后。超过三分之二的患者初诊时分期为广泛期(extensive stage-small cell lung cancer,ES-SCLC)。小细胞肺癌治疗进展缓慢,含铂化疗一直是标准治疗方案,虽然近期有效率高,但易出现耐药。近年来免疫治疗及抗血管药物的兴起,在SCLC领域出现了突破,为SCLC建立新的治疗标准。本文将SCLC的化学治疗、抗血管治疗及免疫治疗进展进行综述。

Small cell lung cancer(SCLC) has a very high proliferation rate,a strong tendency to metastasise early and a poor prognosis.More than two-thirds of patients are initially diagnosed with extensive stage(ES-SCLC).Treatment of small cell lung cancer has progressed slowly and platinum-containing chemotherapy has been the standard of care,which,although recently highly effective,is prone to drug resistance.The rise of immunotherapy and anti-vascular agents in recent years has led to breakthroughs in the field of SCLC,establishing a new standard of care for SCLC.This article reviews advances in chemotherapy,anti-vascular therapy and immunotherapy for SCLC.